This report lists the top Cell Therapy companies based on the 2023 & 2024 market share reports. Mordor Intelligence expert advisors conducted extensive research and identified these brands to be the leaders in the Cell Therapy industry. Buy Now Download Free PDF Now ...
Unlike other gene therapy companies, CRISPR doesn’t take an aggressive approach to differentiating itself from its competitors either. This company prioritizes valuable partnerships, actively seeking out and working with well-known organizations like Vertex and Bayer to achieve new things. The company,...
Released: 2023 Directed by: Andrew Haigh Also ranks #4 on The Best Drama Movies Of 2023 Also ranks #9 on The Best Romantic Drama Movies Of 2023 Also ranks #27 on The 50+ Best London-Based Movies 60 Jeffrey Steven Weber, Michael T. Weiss, Irma St. Paule 557 votes Jeffrey (Steven Web...
It already has three FDA-approved gene-editing therapies. Its Zynteglo therapy treats TDT and its Skysona therapy treats cerebral adrenoleukodystrophy. Bluebird also gained FDA approval in December 2023 for gene-editing therapy lovotibeglogene autotemcel (lovo-cel) in treating SCD in patients ages...
WORLD CELL THERAPY 2025 welcomes you to the International Conference in Paris on March 17-18, 2025, featuring Molecular Cloning, Bioinformatics, Genetics challenges with global speakers and delegates.
An August 2023 report from market research firm Roots Analysis revealed that “over 1,000 cell and gene therapy candidates are currently being investigated for the treatment of various disease indications.. Analysts at Roots Analysis, a pharmaceutical research and consulting firm, predict the mRNA the...
An August 2023 report from market research firm Roots Analysis revealed that “over 1,000 cell and gene therapy candidates are currently being investigated for the treatment of various disease indications.. Analysts at Roots Analysis, a pharmaceutical research and consulting firm, predict the mRNA the...
From Merck & Co to Sanofi, Pharmaceutical Technology lists the leading pharmaceutical companies spending the most on R&D in 2023.
The second swing belongs to Amsterdam-based uniQure, which is developing the first-ever adeno-associated virus (AAV) gene therapy for Huntington’s. AMT-130 is currently in Phase I/II trials in the U.S. with a clinical update expected in Q2, 2023. In August 2022, uniQure paused enrollme...
Introducing our 2023 list of promising companies tackling problems worth solving. Check out the list The Background We launched the first On Deck fellowship in 2019. Throughout it all we have helped start and accelerate hundreds of companies that are now worth over $9 billion. In an effort to...